



PTO/SB08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paper Work Reduction Act of 1995, no person are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICATION (Use as many sheets as necessary)				Application Number	10/735,577
				Filing Date	12/12/2003
				First Named Inventor	David Waisman
				Art Unit	1632
				Examiner Name	Tracy A. Vivlemore
Sheet	1	of	1	Attorney Docket Number	101982

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appeal
		Number-Kind Code ² (if known)			
TV	U	4,462,980	07/31/1984	Diedrichsen et al.	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, columns, lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)					

Examiner Signature	/Tracy Vivlemore/	Date Considered	07/07/2006
-----------------------	-------------------	--------------------	------------

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the authority (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
TV	V	BALLAGAMBA et al., "Tyrosine phosphorylation of annexin II tetramer is stimulated by membrane binding." J Biol Chem., 1997, Vol. 272, No. 6, pp. 3195-9.	
	W	BROOKS et al., "Ca ²⁺ -dependent and phospholipid-independent binding of annexin 2 and annexin 5." Biochem J., 2002, Vol. 367, Pt 3, pp. 895-900.	
	X	CAO et al., "Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells." J Biol Chem., 1996, Vol. 271, No. 46, pp. 29461-7.	
	Y	FALCONE et al., "Macrophage formation of angiostatin during inflammation. A byproduct of the activation of plasminogen." J Biol Chem., 1998, Vol. 273, No. 47, pp 31480-5.	
	Z	GATELY et al., "The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin." Proc Natl Acad Sci U S A, 1997, Vol. 94, No. 20, pp 10868-72.	
	AA	JOHNSSON et al., "Alkylation of cysteine 82 of p11 abolishes the complex formation with the tyrosine-protein kinase substrate p36 (annexin 2, calpactin 1, lipocortin 2)." J Biol Chem., 1990, Vol. 265, No. 24, pp. 14464-8.	
	AB	KASSAM et al., "Characterization of the heparin binding properties of annexin II tetramer." J Biol Chem., 1997, Vol. 272, No. 24, pp. 15093-100.	
	AC	KWON et al., "p22 is a novel plasminogen fragment with antiangiogenic activity." Biochemistry, 2001, Vol. 40, No. 44, pp. 13246-53.	
	AD	Soff, "Angiostatin and angiostatin-related proteins." Cancer Metastasis Rev., 2000, Vol. 19, No. (1-2), pp. 97-107.	
	AE	STATHAKIS et al., "Angiostatin formation involves disulfide bond reduction and proteolysis in kringle 5 of plasmin." J Biol Chem., 1999, Vol. 274, No. 13, pp. 8910-6.	
	AF	TERATANI et al., "Induced transcriptional expression of calcium-binding protein S100A1 and S100A10 genes in human renal cell carcinoma." Cancer Lett., 2002, Vol. 175, No. 1, pp. 71-7.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and no considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. patent and Trademark Office, PO Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.